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1. Introduction 
General Overview of iron homeostasis 
Iron is the most abundant transition metal in cellular systems and is an essential 
micronutrient required for many cellular processes including DNA synthesis, oxidative cell 
metabolism, haemoglobin synthesis and cell respiration. Despite iron being an absolute 
requirement for almost all organisms, caution should be taken with an inappropriate 
disequilibrium in iron levels because excess iron is toxic and a lack of it leads to anaemia. 
As a transition metal, iron can exist in various oxidation states (from -2 to +6). Usually, iron 
exists and switches between two different ionic states (Fe+2 and Fe+3). Iron in the reduced 
state is known as ferrous iron and has a net positive charge of two (Fe+2). In the oxidized 
state it is known as ferric iron and has a net positive charge of three (Fe+3). This electron 
switch property of iron as a metal element allows it to be used as a cofactor by many 
enzymes involved in oxidation-reduction reactions and also confers its toxicity. Iron toxicity 
relates to the intracellular labile iron pool (LIP), a pool of transitory, chelatable (i.e. free) and 
redox-active iron that can catalyze the formation of oxygen-derived free radicals via the 
Fenton reaction. Iron-catalyzed oxidative stress causes lipid peroxidation, protein 
modifications, DNA damage (promoting mutagenesis) and depletion of antioxidant 
defences.  
Iron containing proteins can be classified into 3 groups (for an extensive revision see 
(Crichton, 2009)): 
Haemoproteins, in which iron is bound to four ring nitrogen atoms of a porphyrin molecule 
called haem and one or two axial ligands from the protein. Examples of haemoproteins are 
the oxygen transport protein haemoglobin, the muscle oxygen storage protein myoglobin, 
peroxidases, catalases and electron transport proteins such as the cytochromes a, b and c. 
Iron-sulphur proteins are proteins that contain iron atoms bound to sulphur forming a 
cluster linked to the polypeptide chain by thiol groups of cysteine residues or to non-protein 
structures by inorganic sulphide and cysteine thiols. Examples of iron-sulphur proteins are 




Non-haem non iron-sulphur proteins, these proteins can be of three types:  
Mononuclear non-haem iron enzymes such as catechol or Rieske dioxygenases, alpha-keto 
acid dependent enzymes, pterin-dependent hydrolases, lipoxygenases and bacterial 
superoxide dismutases 
Dinuclear non-haem iron enzymes, also known as diiron proteins, like the H-ferritin chain, 
haemerythrins, ribonucleotide redictase R2 subunit, stearoyl-CoA desaturases and 
bacterial monoxygenases 
Proteins involved in ferric iron transport, for instance the transferrin family that includes 
serotransferrin, lactotransferrin, ovotransferrin and melanotransferrin and are found in 
physiological fluids of many vertebrates. 
As previously mentioned, many proteins involved in very different cellular pathways 
contain iron. Therefore, cells require iron to function properly. However, mammals have no 
physiological excretion mechanisms to release an excess of iron and consequently, iron 
homeostasis must be tightly controlled on both the systemic and cellular levels to provide 
just the right amounts of iron at all times. If an adequate balance of iron is not achieved, it 
will cause a clinical disorder. Iron is therefore crucial for health. Iron deficiency leads to 
anaemia —a major world-wide public health problem— and iron overload is toxic and 
increases the oxidative stress of body tissues leading to inflammation, cell death, system 
organ dysfunction, and cancer (Hentze et al., 2010).  
Systemic iron homeostasis is regulated by the hepcidin/ferroportin system in vertebrates 
(Ganz & Nemeth, 2011). Hepcidin is a liver-specific hormone secreted in response to iron 
loading and inflammation and is the master regulator of systemic iron homeostasis. 
Increased hepcidin levels result in anaemia while decreased expression is a causative feature 
in most primary iron overload diseases. Transcription of hepcidin in hepatocytes is 
regulated by a variety of stimuli including cytokines (TNF-ǂ, IL-6), erythropoiesis, iron 
stores and hypoxia (De Domenico et al., 2007). At the molecular level, the binding of 
hepcidin to the iron exporter ferroportin (FPN) induces its internalization and degradation; 
and thus prevents iron entry into plasma (Nemeth et al., 2004).  
Cellular iron homeostasis is mainly controlled by a system composed of RNA binding 
proteins and RNA binding elements that constitutes a post-transcriptional gene expression 
regulation system known as the Iron Regulatory Protein (IRP) / Iron-Responsive Element 
(IRE) regulatory network (Hentze et al., 2010; Muckenthaler et al., 2008; Recalcati et al., 
2010). This chapter will focus on the IRP/IRE regulatory network, addressing in depth, its 
role in the regulation of cellular iron homeostasis, its alterations in diseases and new 
research lines to be explored in the future. 
2. Cellular iron homeostasis 
Cellular iron maintenance involves the coordination of iron uptake, utilization, and storage 
to ensure appropriate levels of iron inside the cell. Although transcriptional regulation of 
iron metabolism has been reported in the literature; cellular iron homeostasis is mainly 
controlled at the post-transcriptional level (Muckenthaler et al., 2008). In general, post-
transcriptional regulation ensures a faster and easier way of controlling protein expression 
levels in mammalians by changing the rate of specific mRNA synthesis using repressor or 
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stabilizer proteins. Particularly in iron metabolism, this system involves the so-called 
IRP/IRE regulatory network. 
2.1 The IRP/IRE regulatory network 
The Iron Regulatory Protein (IRP) / Iron-Responsive Element (IRE) regulatory network is 
a post-transcriptional gene expression regulation system that controls cellular iron 
homeostasis. This network comprises two RNA binding proteins called Iron Regulatory 
Proteins (IRP1 and IRP2) and cis-regulatory RNA elements, named Iron-Responsive 
Elements, or IRE, that are present in mRNAs encoding for important proteins of iron 
homeostasis. 
IRP/IRE interactions regulate the expression of the mRNAs encoding proteins for iron 
acquisition (transferrin receptor 1, TFR1; divalent metal transporter 1, Slc11a2), iron storage 
(H-ferritin, Fth1; L-ferritin, Ftl), iron utilization (erythroid 5-aminolevulinic acid synthase, 
Alas2), energy (mitochondrial aconitase, Aco2; Drosophila succinate dehydrogenase, Sdh), 
and iron export (ferroportin, Fpn-Slc40a1) (Figure 1) (Muckenthaler et al., 2008). Less well 
known is the role of the IRP/IRE regulatory network in the control of other pathways (for 
details see section 2.1.3.5).  
The IRE binding activities of IRP1 and IRP2 are regulated by intracellular iron levels and 
other stimuli (including nitric oxide, oxidative stress, and hypoxia) through distinct 
mechanisms (for details see sections 2.1.2.1 and 2.1.2.2). IRP/IRE binding activity is high in 
iron-deficient cells and low in iron-replete cells. When iron levels inside the cells are 
increased the IRPs are unable to bind the IREs, because IRP1 in these conditions assemble an 
iron-sulphur cluster (Fe-S cluster) and it is transformed into a cytosolic aconitase; while IRP2 
is degraded by a mechanism that involves the proteosome (see section 2.1.2.1). Therefore, 
only in iron-starved cells, the IRPs became an IRE binding protein (Figure 1). 
Depending on the location of the IRE in the untranslated regions (UTR), IRP binding 
regulates gene expression differentially. Both IRPs inhibit translation initiation when bound 
to IREs at the 5’UTR by preventing the recruitment of the small ribosomal subunit to the 
mRNA (Muckenthaler et al., 1998). Although the cap binding complex eIF4F can assemble 
when IRP1 is bound to a cap-proximal IRE, the small ribosomal subunit cannot be 
established in the presence of IRP1, which interferes with the bridging interactions that need 
to be established between eIF4F and the small ribosomal subunit. The IRPs association with 
the 3’IREs of the TRF1 mRNA decreases its turnover by preventing an endonucleolytic 
cleavage and its mRNA degradation (Binder et al., 1994). This mechanism of IRP mRNA 
stabilization has not been fully probed for other 3’ IRE-containing mRNAs such as DMT1 
and CDC14A, which only have a single 3’IRE and may require additional factors for their 
regulation. Overall, the regulation of the IRE-binding activities of IRP1 and IRP2 assures the 
appropriate expression of IRP target mRNAs and cellular iron balance. 
The IRP/IRE regulatory system was initially described as a simple post-transcriptional 
regulatory gene expression circuit controlling the production of the ferritins and Transferrin 
Receptor 1. The identification of other mRNAs associated with this system has added 
considerable complexity and has extended the role of the IRPs to interconnect different 





Fig. 1. The iron-regulatory protein/iron-responsive element (IRP/IRE) regulatory system. 
IRP1 and IRP2 bind to IREs in iron-deficient conditions (-Fe). This binding mediates 
translation repression in those mRNAs with an IRE at the 5’ UTR, decreasing their protein 
levels. If the IRE is in the 3’ UTR the IRP binding enhances mRNA stabilization by 
preventing an endonucleotic cleavage in TFR1 mRNA. The exact mechanism of IRP 
regulation in DMT1 and CDC14A mRNA is not yet well known. H-Fer: H-ferritin, L-Fer: L-
ferritin, ALAS2: erythroid-specific delta-aminolevulinate synthase, FPN: Ferroportin, ACO2: 
mitochondrial aconitase 2, HIF2ǂ: Hypoxia inducible factor 2 alpha, TFR1: Transferrin 
Receptor 1, DMT1: divalent metal transporter 1, CDC14A: Cell Division Cycle 14, S. 
Cerevisiae, homolog A. 
2.1.1 Iron-Responsive Elements (IRE) 
Iron-responsive elements or IREs are conserved cis-regulatory mRNA motifs of 25-30 
nucleotides located in the untranslated regions (UTR) of mRNAs that encode proteins 
involved in iron metabolism.  
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The mRNAs of H-ferritin (FTH1), L-ferritin (FTL), erythroid-specific delta-aminolevulinate 
synthase (ALAS2), ferroportin (FPN), mitochondrial aconitase 2 (ACO2), and others (see 
section 2.1.3.5) contain one single IRE in their 5´UTRs (Figure 1 and 2). The mRNA encoding 
for Transferrin Receptor 1 (TFR1) is so far the only known mRNA with multiple (five) IREs, 
all of them located in its 3´UTR. The mRNA encoding for DMT1 protein (gene SLC11A2) 
also contains a single IRE in its 3´UTR (Figure 1 and 2). In addition, a single 3’ IRE has been 
reported in other not so well documented mRNAs (see section 2.1.3.5). 
 
Fig. 2. Functional Iron-Responsive Elements (IREs) and the role of their encoded protein. Note 
all motifs contain the characteristic C-bulge (C8) present in the stem motif and a 6-nucleotide –
CAGAGU/C- apical loop both circled in blue. 5’ IREs are shown at the top of the figure and 3’ 
IREs at the bottom. The 5 IREs from TFR1 mRNAs are depicted and named as IRE-A to IRE-E. 
Nucleotides shown in blue represent changes in mouse with respect to the human sequence. 
The function of the encoded protein is shown in red. FTL: L-Ferritin, FTH:H- Ferritin, e-
ALAS2: erythroid-specific delta-aminolevulinate synthase, ACO2: mitochondrial aconitase 2, 
dSdhB: Drosophila succinate dehydrogenase B, FPN: Ferroportin, HIF2ǂ: Hypoxia inducible 
factor 2 alpha, TFR1: Transferrin Receptor 1, DMT1: divalent metal transporter 1.  
The canonical IRE hairpin-loop is composed of a six-nucleotide apical loop (5’-CAGWGH-3’; 
whereby W stands for A or U and H for A, C or U) on a stem of five paired nucleotides, a 
small asymmetrical bulge with an unpaired cytosine on the 5’strand of the stem, and an 




forms base pairs of moderate stability, and folds into an ǂ-helix (Figure 3B) distorted by the 
presence of a small 5’ bulge (an unpaired C8 nucleotide) in the middle of the IRE. IRE base 
pairs can be Watson-Crick bonding or wobble pairs (U.G or G.U). The IRE (CAGWGH) 
terminal loop forms a pseudotriloop (AGW) isolated by a conserved base pair (C14:G18) 
and followed by an unpaired nucleotide (N19, Figure 3A). The base pair C14:G18 and the 
unpaired nucleotide do not make contact with the protein, which suggests that the bridge 
C14:G18 serves only a structural role for IRP1 recognition (Walden et al., 2006). The 
pseudotriloop and the C8 nucleotide make multiple contacts with IRP1 (for more details see 
section 2.1.2.1). It is most likely that all these important structural details, revealed in the 2.8 
angstrom resolution crystal structure of the IRP1:H-ferritin IRE complex reported by 




Fig. 3. SIREs, Searching for Iron-Responsive Elements, the bioinformatic program for the 
prediction of IREs. A. Schematic representation of an IRE motif, rectangular region indicates 
the IRE core region predicted by SIREs software. C-bulge (C8) and 6 nucleotide apical loop 
are shown within a blue circle. The presence of possible 3’ bulge nucleotides are represented 
as N20b, N21b, N22b and N23b. B. SIREs freely available web-server home page at 
http://ccbg.imppc.org/sires/index.html.  
The differential regulation of the IRPs on the different 5’ and 3’ IREs is discussed in the 
section above. Mutations in the Iron-Responsive Elements disrupt the IRP/IRE regulatory 
system and cause iron-related disorders in humans (for details see sections 3). 
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2.1.1.1 Bioinfomatic predictions of iron-responsive elements 
One of the biggest challenges facing researchers in the study of IREs is the availability of 
fast, reliable approaches to recognising possible IREs in known RNA sequences. Existing 
software tools to predict this type of cis-regulatory element (RNA Analyzer, UTRScan and 
RNAMotif) (Bengert & Dandekar, 2003; Macke et al., 2001; Mignone et al., 2005) are not 
sufficiently accurate to find atypical IREs due to their strict constraints for pattern matching 
searches. Therefore, these programs fail to identify mRNAs that have an atypical IRE with 
an unpaired 3’ bulged nucleotide in the upper stem, such as the HIF2ǂ IRE (see Figure 2). In 
addition, previous SELEX (systematic evolution of ligands by exponential enrichment) 
experiments have reported that the six-nucleotide apical loop of an IRE can differ from the 
canonical CAG(U/A)GN sequence and still bind efficiently to IRPs in vitro (Butt et al., 1996; 
Henderson et al., 1996). Furthermore, current IRE prediction programs do not allow for the 
presence of a mismatch pair of nucleotides in the upper stem, although the IRE reported in 
the Gox mRNA contains one such mismatch (Kohler et al., 1999) (see Figure 5).  
To overcome these limitations, the laboratory of Dr. Mayka Sanchez has created new 
software for the prediction of IREs which is implemented as a user-friendly web server tool. 
The SIREs (Search for iron-responsive elements) web server uses a simple data input 
interface and provides structural analysis, predicts RNA folds, folding energy data and an 
overall quality flag based on properties of well characterized IREs. The SIREs algorithm is 
implemented on a Perl script that screens for a 19 or 20 nucleotide sequence motif 
corresponding to the core sequence of an IRE (positions n07–n25) that includes the hexa-
apical hairpin loop (n14–n19), the upper stem, the cytosine bulge (C8) and the lower base 
pair (n07–n25) (see Figure 3A). This core IRE region is sufficient to identify known IREs 
assigning them an equal RNA binding hierarchy as recently reported between IRP1 and 5’ 
IREs (Goforth et al., 2010). The SIREs results are displayed in a tabular format and as a 
schematic visual representation that highlights important features of the IRE. The major 
advantage of the SIREs program is that it is able to detect canonical and non-canonical IREs 
because it integrates and allows the combination of several experimentally reported IRE 
structures without losing stringency in its predictions. Therefore, with this new 
bioinformatic software one can screen an input sequence for the existence of IRE structures 
and will receive a scored output (as a high, medium or low) of the predicted IRE for 
prioritization of further studies (see Figure 3B for the home page of the SIREs website).  
Overall, the SIREs web server represents a significant improvement on currently available 
programs to predict IREs, providing the scientific community with an easy-to-use 
bioinformatics platform to identify putative IRE motifs that can then be subjected to further 
experimental testing in vitro and in vivo. The SIREs web server is freely available on the web 
at: http://ccbg.imppc.org/sires/index.html (Figure 3) and was published by Campillos and 
collaborators (Campillos et al., 2010). 
2.1.2 Iron regulatory proteins: IRP1 and IRP2 
Iron regulatory proteins 1 and 2 (IRP1 and IRP2) are proteins sensitive to cytosolic iron 
concentrations that post-transcriptionally regulate the expression of iron metabolism genes 
to optimize cellular iron availability. IRP1 is encoded by the gene ACO1 found in 




deficient cells, IRPs bind to iron-responsive elements (IREs) found in the mRNAs of ferritin, 
transferrin receptor and other iron metabolism transcripts, enhancing iron uptake and 
decreasing iron sequestration. IRP1 registers cytosolic iron status mainly through an iron-
sulphur cluster switch mechanism, alternating between an active cytosolic aconitase form 
with an iron-sulphur cluster ligated to its active site and an apo-protein form that binds 
IREs. Although IRP2 is 60 to 70% identical to IRP1 (one of the major difference is an extra 73 
amino acid insertion present in IRP2), both proteins are differentially regulated. IRP2 does 
not have an aconitase function and its activity is regulated primarily by iron-dependent 
degradation through a ubiquitin-proteasomal system in iron-replete cells (see next section).  
Constitutive deletion of both IRPs is embryonic lethal, demonstrating that the IRP/IRE 
regulatory system is essential for life (Galy et al., 2008; Smith et al., 2006). The groups of 
Matthias W. Hentze (EMBL) and Tracey Rouault (NIH) have reported knock-out targeted 
deletion strategies for IRP1 and/or IRP2 in whole animals or tissue specific. Their 
publications show that adult mice that constitutively lack IRP1 develop no overt 
abnormalities under standard laboratory conditions; however, IRP2 KO mice developed 
microcytic anaemia, elevated red cell protoporphyrin IX levels, high serum ferritin, and 
adult-onset neurodegeneration. When mice are missing both copies of IRP2 and one copy of 
IRP1 they develop a more severe anaemia and neurodegeneration compared with mice with 
deletion of IRP2 alone (Smith et al., 2006). At the cellular level, Galy and collaborators 
reported that mitochondrial iron supply and function also require IRPs for cellular ATP, 
haem and iron-sulphur cluster production (Galy et al., 2010). 
Both IRPs are expressed in all tissues, however IRP1 is particularly abundant in kidney and 
brown fat, and IRP2 expression is higher in brain, intestine, and cells of the 
reticuloendothelial system (reviewed in (Cairo & Pietrangelo, 2000)).  
2.1.2.1 Structure and regulation of IRPs by iron 
IRP1 is a dual-functional protein with a key role in the control of iron metabolism as an IRE-
binding protein and with an additional function as a cytoplasmic isoform of the aconitase 
enzyme (Figure 4). Aconitases are a group of iron-sulphur enzymes that require a 4Fe-4S 
cluster (iron-sulphur cluster, ISC) for their function. The ISC is essential to catalyse the 
conversion of citrate to isocitrate via the intermediate cis-aconitate during the citric acid 
cycle. Three iron atoms are attached to cysteine residues of the active site, whereas a fourth 
iron remains free and mediates catalytic chemistry (reviewed in (Eisenstein, 2000)). IRP1, as 
cytosolic aconitase (c-aconitase), catalyses the citrate to isocitrate conversion in the cytosol 
and shares 30% amino acid sequence homology with mitochondrial aconitase (m-aconitase), 
which catalyzes the same reaction in the mitochondrial matrix. In contrast with m-aconitase, 
IRP1 only retains its ISC and enzymatic function in iron-replete cells, and thus only 
functions as a cytosolic aconitase when cells have high levels of iron. Under iron scarcity, 
the ISC dissemble from holo-IRP1 and the protein is converted into IRP1 apo-protein, 
acquiring IRE-binding ability. Hence, IRP1 is reversibly regulated by this unusual ISC 
switch (Wallander et al., 2006).  
The IRP1 protein is composed of four globular domains. In its c-aconitase form, domains 1–3 
are compact and join domain 4 through a polypeptide linker and the ISC is central at the 
interface of the four domains. The ISC structure and surrounding environment are fairly 
well conserved between c- and m-aconitases. Nevertheless, the overall structure of holo-
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IRP1 (a 889 amino acid protein), shows differences to m-aconitase, which is smaller (780 
amino acids). The short IRP1 fragments that do not superimpose with m-aconitase are 
exposed on the surface of the protein. As a result, the shapes and surface topologies of holo-
IRP1 and m-aconitase diverge substantially, which may explain the fact that IRP1 is the only 
aconitase that can acquire IRE binding activity.  
 
Fig. 4. Iron regulation of Iron-Regulatory Proteins IRP1 and IRP2. Under iron depleted 
conditions (-Fe) IRP1 and IRP2 bind to IREs. IRP1 is a bi-functional protein acting as an 
aconitase when it assembles an iron-sulphur cluster (4Fe-4S) or as an IRE binding protein. 
IRP2 undergoes proteosomal degradation via ubiquitinization (Ub) when iron (Fe) and 
oxygen (O2) levels are high. FBXL5: F-Box and leucine rich repeat protein 5, SKP1: S-Phase 
kinase-associated protein 1, CUL1: Cullin 1.  
IRP1 apo-protein shows an open conformation compared with that of cytosolic aconitase, 
allowing its interactions with IREs and controlling the gene expression of key proteins of 
iron metabolism. IRP1: H-ferritin IRE crystal structural complex has been resolved at a 
resolution of 2.8Å and the details of its reorganization upon loss of its ISC has been 
described by Walden and collaborators (Walden et al., 2006). IRP1 conformational changes 
after loss of its ISC reveals a rotation of domain 4 and an extensive rearrangement of domain 
3, creating a hydrophilic cavity that allows access to the IRE (Figure 4). The RNA–protein 
interaction requires two important segments at the interface of domain 2 (residues 436–442) 
and domain 3 (residues 534–544). Thr438 and Asn439 make direct contact with the IRE. The 
terminal residues of the IRE motif, A15, G16 and U17 (see figure 3A), interact with Ser371, 




site is present around the unpaired-C-bulge residue (C8 bulge, Figure 3A) located between 
the upper and lower stem, which occupies a pocket within domain 4, involving residues 
between Arg713 and Arg780. The IRE–IRP1 complex is also stabilized by additional ionic 
interactions. The evolutionary origin and selective advantage of the IRP1 dramatic 
conformational plasticity and dual functionality remains to be determined. 
A second IRE-binding protein first named IRFB and lately renamed as IRP2 was isolated 
and characterized in rodents in 1993 (Henderson et al., 1993). This manuscript also reports 
that IRP1 IRE binding activity is predominant in liver, intestine, and kidney, while IRP2 
revealed highest binding activity in intestine and brain. Human IRP2 has a molecular mass 
of 105 kD, slightly larger than human IRP1 (87kD) due to an extra 73 amino acid insertion. 
Human IRP2 shares 57% homology with human IRP1. Despite this homology, IRP2 is 
unable to assemble an iron-sulphur cluster and thus has no aconitase activity. IRP1 and 
IRP2’s role in controlling mRNA translation and stabilization in IRE-containing mRNAs is 
similar, that is both proteins carry out a translational repression in 5’ IREs and mRNA 
stabilization in 3’ IREs. However unlike IRP1, IRP2 is rapidly targeted for degradation in 
iron-replete cells (Recalcati et al., 2010). It seems that the mechanism by which IRP2 
undergoes iron-dependent degradation may involve different aspects. The 73 cysteine rich 
amino acid domain of IRP2 may be responsible for this degradation due to its ability to 
facilitate iron-dependent oxidation, ubiquitination, and proteasomal degradation (Wang & 
Pantopoulos, 2011). Recently, two groups have independently identified the protein FBXL5 
as part of the ubiquitin ligase complex that promotes iron-dependent polyubiquitination 
and degradation of IRP2 (Salahudeen et al., 2009; Vashisht et al., 2009) (see Figure 4). As the 
stability of FBXL5 itself is controlled by iron and/or oxygen levels through an iron-binding 
hemerythrin-like domain located in the N-terminus, FBXL5 accumulates when iron is 
plentiful and is degraded upon iron depletion. By this mechanism the presence of FBXL5 in 
iron rich conditions works as a key sensor in the regulation of IRP2 degradation. No crystal 
structure of IRP2 is available as of yet, and forthcoming experiments will allow us to 
elucidate the role (if any) of the extra amino acid residues in IRP2 IRE binding specificity 
and/or their role in protein degradation. Ultimately, the crystallization of IRP2, especially in 
a complex with IRE, will be necessary to precisely map the RNA–protein interactions and 
further shed light on its mechanistic properties (Wang & Pantopoulos, 2011). 
2.1.2.2 Regulation of IRPs by other stimuli than iron 
Iron was the first identified regulator of the IRP/IRE network however various other 
stimuli, drugs and pathological agents have been reported to affect IRP activity. 
Hypoxia  
IRP1 and IRP2 are regulated by oxygen levels (reviewed in (Rouault, 2006)) which control their 
binding activity. Hypoxia has been shown to decrease the binding to IREs in IRP1 by 
favouring the assembly of the ISC and causing IRP1 to acquire aconitase activity, but 
increasing IRP2 activity (Meyron-Holtz et al., 2004). Other studies also reported an opposite 
regulatory effect of hypoxia on IRP1 and IRP2 IRE binding activities, though not all studies 
agree on the direction of this divergent modulation. As described in section 2.1.2.1 IRP2 
degradation is controlled by FBXL5 in an iron- and oxygen-dependent manner, which 
suggests one possible explanation for the differential regulation of the two IRPs by hypoxia. At 
low oxygen concentrations, which favour the assembly of an ISC of IRP1 and stabilise IRP2, 
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the latter regulates iron homeostasis but, at high oxygen concentrations, FBXL5 is stabilised, 
interacts with IRP2 and induces its degradation, whereas the apoform of IRP1 can bind and 
regulate the mRNAs encoding proteins of iron metabolism. These mechanisms may therefore 
allow cells to regulate iron metabolism effectively over a broad range of oxygen availability.  
Hypoxia has also been shown to reduce IRP1 binding to HIF-2ǂ mRNA via a newly 
identified 5’ IRE (see section 2.1.3.5), while slightly increasing binding to IRP2 (Zimmer et 
al., 2008). Interestingly, these authors describe a major effect of IRP1 on de-repression of 
HIF-2ǂ translation in hypoxic conditions, and they suggest that IRP1 acts as a direct or 
indirect sensor of hypoxia, which is somehow contradictory to the previous reported 
predominant role of IRP2 at physiologically low oxygen levels (3%-5%). This work was done 
in the context of renal cells in which IRP1 is particularly abundant, and this may explain the 
main regulatory role of IRP1 in HIF translation during hypoxia. 
Oxidative stress 
Both IRP1 and IRP2 are sensitive to ROS (Reactive Oxygen Species) and RNS (Reactive 
Nitrogen Species) (reviewed in (Cairo & Pietrangelo, 2000)). As explained earlier, the redox 
regulation of IRP1 is mediated by its iron-sulphur cluster (ISC) switch. Exposure of cells to 
H2O2 leads to the removal of ISC and conversion of IRP1 into a null protein lacking both 
RNA binding and aconitase activities. This conversion can be reversed by myeloperoxidase-
derived hypochlorite (Mutze et al., 2003). 
Early studies of exogenous H2O2 exposure to cell lines were shown to increase IRP1 
expression (Cairo & Pietrangelo, 2000) though this was later shown to be a consequence of 
signalling pathway effects rather than direct oxidative stress on IRP1 (Caltagirone et al., 
2001). Successive studies in various cell models have reported a number of agents 
(superoxide, phorone, quinone) (reviewed in (Recalcati et al., 2010)) with the ability to 
increase cellular H2O2 and O2- and reversibly inactivate IRP1. This opens up the question of 
whether IRP1 inactivation (and subsequent TFR1 down-regulation, ferritins up-regulation 
and therefore decreasing LIP) is a homeostatic response to subdue ROS formation.  
ROS studies on IRP2 have revealed seemingly contradictory results to date. Iwai and 
collaborators suggested that ROS triggers down-regulation of IRP2 by alterations to 
“sensitive” amino acid residues leading to ubiquitin-dependent proteasomal degradation 
(Iwai et al., 1998). However, a more recent study reported that treatment of murine 
macrophage cells with exogenous H2O2 protects IRP2 against iron and increases its IRE-
binding activity (Hausmann et al., 2011). Moreover, they also showed that IRP2 is stabilized 
during menadione-induced oxidative stress suggesting that the degradation of IRP2 in iron-
replete cells is not only oxygen-dependent but also sensitive to redox perturbations. Overall, 
further in-depth analysis of the exact role of oxidative stress is needed to properly evaluate 
its specific role in iron homeostasis. 
Nitric Oxide 
Nitric Oxide (NO) is a vital signalling and effector molecule that can rapidly switch IRP1 
from its holo- to the apo-form (Drapier, 1997). NO is produced by NO synthases and once 
released, attacks the ISC of IRP1 promoting its gradual disassembly and complete removal 
suggesting this NO-mediated switch could represent a homoeostatic response to iron 




The effect of NO on IRP2 has also been studied, although with contradictory results. Wang 
and collaborators claimed that IRP2 was activated under NO exposure (Wang et al., 2005), 
whereas Kim and collaborators demonstrated that IRP2 degradation was NO-dependent (S. 
Kim et al., 2004). Mulero and collaborators showed that IRP2 had a lack of regulation by NO 
(Mulero & Brock, 1999). Furthermore, it has been reported that endogenous and exogenous 
NO increases (S. Kim & Ponka, 2002) or decreases (Pantopoulos & Hentze, 1995) ferritin 
levels and further discrepant results of TfR1 regulation by NO has been described 
(Pantopoulos & Hentze, 1995). As a result, the role of the IRP/IRE system in NO-mediated 
regulation of cellular iron metabolism still remains unknown.  
Other antioxidants, such as ascorbate, ǂ-tocopherol and N-acetylcysteine have also been 
shown to disturb the IRE/IRP regulation system by promoting the proteasomal turnover of 
IRP2 (Wang et al., 2004).  
Other stimuli that affect IRP regulation: Hormones and viruses 
A number of hormones and viruses have been documented as interacting with IRPs and 
regulating iron metabolism. In an extensive report, in vitro and in vivo studies of the thyroid 
hormone showed that it functionally regulates the IRE binding activity of the IRPs to ferritin 
mRNA (Leedman et al., 1996). Estrogens modulate the RNA binding of IRP1 in adipose 
tissue and consequently the expression of ferritin and TfR1 (Mattace Raso et al., 2009).  
Given the importance of iron in viral infections and replication (Drakesmith & Prentice, 
2008) several studies have outlined the impact of viruses on iron homeostasis. In the case of 
Herpes Virus-1 infection of Madin-Darby bovine kidney cells, IRP RNA binding activity 
was reported to be reduced (Maffettone et al., 2008). However, this effect may be due to 
different factors, as shown in studies on the hepatitis B virus X protein that produced an 
increase in ROS and thus IRP1 down modulation (Gu et al., 2008). Similarly, in a cell culture 
model of hepatitis C virus replication, the down-regulation of TfR1, increased FPN levels 
and reduced LIP were associated with concomitant induction of IRE-binding activity and 
IRP2 expression (Fillebeen et al., 2007). 
Other stimuli that affect IRP regulation: Xenobiotics 
Many studies of xenobiotic effects on the IRP/IRE regulatory system have been performed 
with Doxorubicin (DOX). DOX is an anti-cancer anthracycline that causes a severe form of 
chronic cardiomyopathy. The alcohol metabolite of DOX (DOXol) breaks iron away from the 
iron-sulphur cluster of cytoplasmic aconitase and the O2 free radicals and H2O2 derived 
from the redox activation of DOX convert IRP1 to a null protein (Brazzolotto et al., 2003). In 
another study it was shown that this null protein does not actually rely on the action of 
DOXol but on anthracycline-iron complexes attacking both aconitase and IRP1 (Kwok & 
Richardson, 2002). IRP2 protein does not contain an ISC and is not affected by DOXol, but is 
degraded by the action of the ROS that is produced (Minotti et al., 2001). The ability of DOX 
to regulate the RNA binding activity of IRP1 and IRP2 may also be due to its anti-tumoral 
and cardiotoxic activities. The possibility of combining DOX with other anti-neoplastic 
drugs is currently being tested for clinical applications. 
Other stimuli that affect IRP regulation: Cell growth  
Iron homeostasis and cell growth are interrelated because iron is essential for cell 
proliferation and is especially required in neoplastic cells as they proliferate faster and thus 
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require elevated iron supplies. This is demonstrated by a higher expression of TfR1 and 
higher transferrin iron uptake in cancer cells. In addition, iron is required for the function of 
many proteins involved in cell cycle and DNA synthesis (e.g. Ribonucleotide Reductase). 
Moreover, iron appears to play a critical role in the expression and regulation of a number of 
molecules that control cell cycle progression e.g. p53, GADD45 and WAF1/p21 (Gao et al., 
1999). In fact, without iron, cells are unable to proceed from G1 to the S phase of the cell 
cycle due to post-transcriptional regulation caused by iron depletion in cyclin D1 expression 
(a protein that plays a critical role in G1 progression) (Nurtjahja-Tjendraputra et al., 2007).  
The cell cycle further manipulates the IRP/IRE regulatory system as IRP2 is phosphorylated 
at Ser 157, independently of iron levels, by Cdk1/cyclin B1 during the G2/M phase of the 
cell cycle, and in turn dephosphorylated by CDC14A after mitosis. This reduces IRP2 RNA 
binding activity in the G2/M phase of the cell cycle, increasing ferritin synthesis and 
impairing TfR1 mRNA stability (Wallander et al., 2008). Therefore, it seems that this 
reversible phosphorylation of IRP2 facilitates cell cycle progression. It has been shown that 
IRP activity is high in a classical model of non-neoplastic cell growth such as liver 
regeneration (Cairo & Pietrangelo, 1994). Cell proliferation induces IRP2 activity possibly 
because of the combined effect of high iron consumption in growing cells and IRP2’s 
preferential sensitivity to iron deprivation (Recalcati et al., 1999). However, the fact that 
IRP2 transcription is specifically stimulated by a c-myc oncogene (Wu et al., 1999) suggests 
that the induction of IRP2 activity (with consequent ferritin repression and TfR1 up-
regulation) may be specifically aimed at ensuring sufficient iron for the metabolic 
requirement of proliferating cells.  
In 2006, Sanchez and collaborators reported a novel IRE located in the 3' UTR of the cell 
division cycle 14A (CDC14A) mRNA that efficiently binds both IRP1 and IRP2 (Sanchez et 
al., 2006) (see also section 2.1.3.5). Differential splicing of CDC14A produces IRE- and 
non-IRE-containing mRNA isoforms. Interestingly, only the expression of the IRE-
containing mRNA isoforms is selectively increased by cellular iron deficiency. This 
uncovered a previously unrecognized regulatory link between iron metabolism and the 
cell cycle. 
2.1.3.1 The IRP/IRE regulatory network in iron uptake 
The main cellular iron uptake pathway is mediated by Transferrin Receptor 1 (TFR1, gene 
located on chromosome 3q29), which internalises iron-bound transferrin (TF) via a receptor-
mediated endocytosis mechanism (Ponka et al., 1998). Iron-loaded transferrin binds with 
high affinity to TFR1 on the surface of cells, and the complex undergoes endocytosis via 
clathrin-coated pits. Once inside the endosome, a proton pump lowers the pH to 5.5, 
resulting in the release of Fe3+ from transferrin. Subsequently, the affinity of transferrin to 
TFR1 falls about 500-fold, resulting in its de-attachment of the TFR1-TF complex. In the final 
step of the cycle, non-iron bound transferrin is secreted into the bloodstream to recapture 
more Fe3+ and the transferrin receptor 1 protein is again relocated in the cell surface for 
another round of endocytosis. 
TFR1 is expressed in many cells and plays a relevant function in erythroid iron acquisition 
for haem synthesis and haemoglobinization. Its expression parallels the maturation of 
erythroid progenitors and is involved in the development of erythrocytes and the nervous 




Knockout mice homozygous for a null mutation in the transferrin receptor 1 (Tfr1) gene die 
after 12.5 days from severe anaemia and neurological abnormalities during embryonic 
development (Levy et al., 1999). These mice have a more severe phenotype than 
homozygous hypotransferrinaemic (hpx/hpx) mice that carry a mutation in the transferrin 
gene and have a severe reduction of transferrin expression. Haploinsufficiency for Tfr1 
(Trfr+/–) results in impaired erythroid development with microcytic, hypochromic 
erythrocytes and abnormal iron homeostasis with mild tissue iron depletion in liver and 
spleen. In this regard, Trfr+/– mice differ from hpx/hpx and +/hpx mice, which have 
increased intestinal iron absorption leading to tissue iron overload.  
TFR1 expression is controlled by iron and oxygen status amongst other factors (Cairo & 
Pietrangelo, 2000). At the transcriptional level, TFR1 is regulated by the hypoxia-inducible 
factor HIF1 in response to low oxygen levels and iron starvation (Bianchi et al., 1999). In 
addition, the TFR1 promoter region contains potential binding sites for transcription factors 
such as c-myc (O'Donnell et al., 2006). Nevertheless, in most cells TFR1 expression is mainly 
controlled post-transcriptionally by cellular iron levels through binding of IRP1 and IRP2 to 
five IREs located in the 3’ UTR of the TFR1 mRNA (see Figure 2). TFR1 mRNA is stabilized 
by the binding of IRPs under iron-starved conditions by a mechanism that involves the 
protection of the mRNA degradation by a cleavage of a putative, as yet unidentified, 
endonuclease (Figure 1). This mechanism will ensure an increased expression of TFR1 in the 
cell surface to stimulate the acquisition of iron from plasma transferrin, and it will be 
blocked in iron-replete cells. However, the IRP/IRE regulation of TFR1 mRNA is overridden 
in specialized cells such as the erythroid progenitor cells, where TFR1 mRNA stability is 
uncoupled from iron supply and IRP regulation to ensure efficient massive iron uptake 
needed in these cells for haem synthesis and haemoglobinisation. In these cells TFR1 
expression is regulated transcriptionally by a promoter erythroid active element (Lok & 
Ponka, 2000). 
The SLC11A2 gene, located on chromosome 12q13, encodes a member of the solute carrier 
11 protein family named Divalent Metal Transporter 1 (DMT1) or natural resistance-
associated macrophage protein 2 (Nramp2). DMT1 is a glycoprotein that consists of twelve 
transmembrane domains and transports reduced ferrous iron (Fe+2) and other divalent 
metals (manganese, cobalt, nickel, cadmium, lead, copper, and zinc) to the inside of 
duodenal enterocytes, where it is highly expressed at the apical (luminal) site (Mackenzie & 
Garrick, 2005).  
Inorganic iron absorption via DMT1 is an important iron uptake pathway, as observed in 
homozygous mk/mk mice that have microcytic, hypochromic anaemia due to severe defects 
in intestinal iron absorption and erythroid iron utilization. By positional cloning, Fleming 
and collaborators discovered in 1997 that a missense mutation in the gene Nramp2 was 
responsible for the mk mouse phenotype (Fleming et al., 1997). One year later the same 
group also reported that a similar phenotype present in Belgrade (b) rats was due to the 
same missense mutation, a glycine-to-arginine missense mutation (G185R), in the Nramp2 
gene (Fleming et al., 1998). Functional studies of the protein encoded by the mutated b allele 
of rat Nramp2 demonstrated that the mutation disrupted iron transport. Therefore, the 
phenotypic characteristics of mk mouse and Belgrade rats indicate that Nramp2 is not only 
essential for normal intestinal iron absorption but also for transport of iron out of the 
transferrin cycle endosome. 
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DMT1 is a conserved transporter in vertebrates and the phenotype called chardonnay (cdy) 
in zebrafish mutants with hypochromic, microcytic anaemia is due to a nonsense mutation 
in DMT1. The truncated DMT1 protein expressed in cdy mutants is not functional (Donovan 
et al., 2002). In humans, mutations in this gene are associated with hypochromic microcytic 
anaemia with iron overload. This is a very rare disease so far described in only five subjects 
(OMIM 206100).  
The SLC11A2 gene encodes four transcripts that are the result of alternative splicing at the 5’ 
or 3’ end, yielding DMT-1A-IRE, DMT-1B-IRE, DMT-1A-nonIRE, and DMT-1B-nonIRE 
isoforms. The different isoforms of DMT1 are differentially expressed in tissues, increasing 
somewhat the complexity of the study of this gene (Hubert & Hentze, 2002). One of the two 
3’ splicing forms (the IRE isoform) contains an IRE structure in its 3’ UTR (see Figure 2) and 
is up-regulated by iron deficiency via the IRPs (Mackenzie & Garrick, 2005); however, the 
regulation of DMT1 is very complex and both transcriptional and post-transcriptional 
regulations may be involved in its gene expression regulation. The ablation of both IRPs in 
intestinal epithelial cells reduces the levels of IRE-containing DMT1 mRNA and DMT1-
dependent intestinal iron uptake (Galy et al., 2008), but transcriptional regulation may be 
important, as is also suggested by recent studies showing that HIF2ǂ–dependent DMT1 
transcription plays a role in intestinal iron uptake (Mastrogiannaki et al., 2009).  
2.1.3.2 The IRP/IRE regulatory network in iron storage 
In addition to iron recycling and absorption, the storage and potential release of (excess) 
iron are critical determinants of circulating iron levels. Under physiological conditions, 
approximately 20% (0.5 to 1g) of the body’s total iron content is stocked in the storage 
compartment, and only 1 to 2mg of iron is lost each day. The iron stores become depleted 
when iron absorption does not meet the body’s needs or in cases of excessive iron loss (e.g. 
bleeding, pregnancy); conversely, tissue iron overload occurs when intestinal iron 
absorption surpasses iron utilization and loss (Andrews, 2010). Iron storage should be 
therefore tightly controlled to avoid an iron imbalance that will lead to a disease stage. 
Ferritins are the major iron storage protein, and are found in the cytoplasm, mitochondria, 
and nucleus of the cells (Arosio et al., 2009). In vertebrates, cytoplasmic ferritin is expressed 
in almost all tissues and plays an important role in the control of intracellular iron 
distribution. Ferritin consists of a 24-subunit heteromultimer of light (L) and heavy (H) 
chains (174 and 182 amino acids respectively) that form a spherical shell around a cavity 
where iron (as ferric oxide) is stored. Each subunit has a distinct role in iron metabolism: L-
ferritin facilitates iron-core formation and H-ferritin subunit generates ferroxidase activity 
(converting Fe+2 to Fe+3) to incorporate iron into the protein shell. Plant and bacteria ferritins 
have only a single type of subunit which probably fulfils both functions. L- and H-ferritin 
subunits are synthesized by two different genes located on chromosomes 19q13.2 and 11q13, 
respectively. Although both genes are ubiquitously expressed, post-transcriptional 
regulation mediates tissue-specific changes in the H/L mRNA ratio.  
The best characterized system regulating ferritin expression is the post-transcriptional, iron-
dependent machinery based on the interaction between the IRPs and IREs localized in the 5’ 
untranslated region of H- and L-ferritin mRNA (Muckenthaler et al., 2008) (see Figure 1 and 
2). Iron deficient cells need to rapidly mobilize the iron storage pool and in these conditions 




IRP/IRE complexes in the 5’UTR of ferritins that inhibits translation in iron-starved cells. 
Mechanistically, this translational block is due to the IRP interference in the recruitment of 
the small ribosomal subunit to the mRNA by preventing the interactions between the cap 
binding complex eIF4F and the small ribosomal subunit (Muckenthaler et al., 1998). The rate 
of de novo synthesis and abundance of ferritin can change over a 50-fold range in response to 
variations in iron availability mainly via the IRP/IRE regulatory system and thus the 
transcripts of the H- and L-ferritin chains are the prototypes of IRP-mediated translational 
control. 
In vivo disruption of the H-ferritin gene by homologous recombination (Fth-/- mice) is early 
embryonic lethal (Ferreira et al., 2000). Fth -/- embryos die between 3.5 and 9.5 days of 
development, suggesting that there is no functional redundancy between the two ferritin 
subunits and that, in the absence of H subunits, L-ferritin homopolymers are not able to 
maintain iron in a bioavailable and nontoxic form. Fth +/- mice are healthy, fertile, and do 
not differ significantly from their control littermates. To overcome this embryonic lethality 
of Fth -/- mice, the group of Dr. Lukas Kuhn has recently created an intestine-specific H-
ferritin knock-out mouse model (Vanoaica et al., 2010), which shows that not only is 
hepcidin required for an accurate control of iron absorption, but H-ferritin is also critical for 
limiting iron efflux from intestinal cells. These mice with an intestinal H-ferritin gene 
deletion show increased body iron stores and transferrin saturation that resembles 
Hereditary Hemochromatosis (HH). 
In humans defects in the L-ferritin gene are associated with a neurodegenerative disease 
(NBIA3, neurodegeneration with brain iron accumulation 3, OMIM #606159), genetic 
hyperferritinemia without iron overload (Kannengiesser et al., 2009) and hyperferritinemia-
cataract syndrome (HHCS). A mutation in the H-ferritin gene causes the autosomal 
dominant Iron overload syndrome. The hyperferritinemia-cataract syndrome (HHCS, 
OMIM #600886) and the autosomal dominant Iron overload syndrome (OMIM +134770) are 
due to specific mutations in the IRE motif of H- and L-ferritin, respectively and are 
extensively discussed in sections 3.1 and 3.2. 
2.1.3.3 The IRP/IRE regulatory network in iron release 
The transmembrane protein Ferroportin (FPN) is encoded by the SLC40A1 gene 
(chromosome 2q32.2) and this protein is the only known cellular iron exporter (Donovan et 
al., 2005). FPN is ubiquitously expressed, but is more abundant on the basolateral 
membrane of enterocytes in the duodenum and in reticuloendothelial cells. Ferroportin 
plays an important role in iron absorption (i.e. iron transport from enterocytes into the 
plasma) and iron reuse (i.e. iron released out of macrophages and coming from 
erythrophagocytosis of senescent or damaged red blood cells) (Hentze et al., 2010). 
FPN is post-translationally regulated by hepcidin, which plays a central role in controlling 
systemic iron levels. On hepcidin binding, FPN is internalized and degraded (Ganz & 
Nemeth, 2011), thus inhibiting iron efflux from enterocytes, macrophages, and other cells.  
FPN is also regulated at the post-transcriptional level by the IRP/IRE regulatory system 
(Figure 1). FPN mRNA bears a functional IRE motif in its 5’UTR (see Figure 2) that allows it 
to respond to iron manipulations in hepatic, intestinal, and monocytic cells (Lymboussaki et 
al., 2003). Similarly to ferritin IRP control, in iron deprivation the IRP binding to the 
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ferroportin 5’ IRE will inhibit its translation. The simultaneous ablation of IRP1 and IRP2 in 
mice markedly increases intestinal FPN expression, despite the increase in hepatic hepcidin 
expression, indicating that IRPs are as critical as hepcidin for physiological FPN expression 
in the intestine (Galy et al., 2008). The IRP-dependent translational control of FPN 
expression has been found in response to nitric oxide (NO) (X. B. Liu et al., 2002) and 
erythrophagocytosis (Delaby et al., 2008). Duodenal epithelial and erythroid precursor cells 
utilize an alternative upstream promoter to express a FPN1 transcript, FPN1B, which lacks 
the IRE and therefore this FPN isoform will escape the IRP repression in iron-deficient 
conditions (Zhang et al., 2009).   
SLC40A1 gene mutations are associated with an autosomal inherited genetic iron disorders 
described as ferroportin disease. Indeed, ferroportin disease is phenotypically 
heterogeneous with two sub-types. Classical ferroportin disease is the usual form and is 
characterized by hyperferritinemia, normal or low transferrin saturation, and iron overload 
in macrophages. This form is generally asymptomatic with no tissue damage and is due to 
ferroportin mutations that lead to a loss of function. The non-classical ferroportin form is 
rarer and resembles Hereditary Hemochromatosis with hepatocellular iron deposits and 
high transferrin saturation. In this form, ferroportin mutations are responsible for a gain of 
function with full iron export capability but resistance to down-regulation by hepcidin, 
which leads to a phenotype similar to hepcidin deficiency-related HH (i.e. types 1, 2, and 3). 
In fact, the non-classical ferroportin form is also known as Hereditary Hemochromatosis 
type 4. Most of the described mutations in ferroportin are located in the coding region or in 
exon-intron boundaries, only one patient with iron-overload Hereditary Hemochromatosis 
type 4 has been described with a point mutation close to the FPN IRE. This mutation could 
alter the IRE structure and the IRP regulation of FPN, but this was not studied further (Liu 
et al., 2005). In addition, radiation-induced polycythaemia (Pcm) mice were shown to have a 
ferroportin promoter microdeletion that also eliminates the iron-responsive element (IRE) in 
the 5' untranslated region (Mok et al., 2004) (see section 3.3). 
2.1.3.4 The IRP/IRE regulatory network in iron utilization and energy metabolism 
The erythroid iron utilization is also controlled by the IRP/IRE system through the 
interaction with ALAS2 mRNA. ALAS2 (erythroid-specific 5-aminolevulinic acid synthase) 
mRNA encodes for the first and rate-limiting enzyme in the haem biosynthesis pathway. 
This mRNA contains a 5’ UTR IRE (see Figure 1) identified using an in silico approach, and it 
is translationally repressed by the binding of the IRPs in iron-deficient conditions 
preventing the accumulation of toxic intermediates of the haem biosynthesis pathways such 
as protoporphyrin IX (Dandekar et al., 1991). The regulation of the Alas2 mRNA by the IRPs 
is affected in the zebrafish mutant shiraz, which presents severe hypochromic anaemia and 
early embryonic lethality due to defects in the Grx5 gene (Wingert et al., 2005). Grx5 protein 
is required for iron-sulphur cluster assembly and its abrogation shifts IRP1 conformation to 
an IRE-binding protein that leads to Alas2 repression and cytosolic iron depletion that also 
activates IRP2, which will further contribute to the repression of Alas2. A patient with iron 
overload and mild sideroblastic anaemia was described as bearing a homozygous mutation 
that interferes with intron 1 splicing and drastically reduces GLRX5 mRNA levels 
(Camaschella et al., 2007). Surprisingly, in this patient the anaemia was worsened by blood 
transfusions but partially reversed by iron chelation, presumably because iron chelation will 




synthesis and anaemia. These intricate mechanisms reveal the control of the IRP/IRE 
regulatory system in haem biosynthesis during erythroid differentiation, as well as the 
coordination of the regulation of haemoglobin with the iron-sulphur cluster assembly 
machinery. 
The IRP/IRE system also controls energy metabolism by the regulation of two iron-sulphur 
containing enzymes of the tricarboxylic acid cycle (TCA cycle), the mitochondrial aconitase 
Aco2 and the Drosophila succinate dehydrogenase B, SdhB. These two mRNAs contain a 
single 5’ UTR IRE that were identified using the same IRE bio-computational searching 
approach as previously mentioned (Gray et al., 1996) (see Figure 1). The translational 
regulation of these mRNAs by the IRPs may co-ordinate their expression with iron 
availability since these are iron-containing enzymes, and altogether influence energy 
metabolism. 
There is evidence that the translational repression exerted by the IRPs varies depending on 
the targeted mRNA. For instance, IRP regulation of ferritin transcripts is stronger than IRP 
Aco2 repression (Schalinske et al., 1998), this is in part due to differences in binding 
affinities of the IRPs for each particular transcript (Goforth et al., 2010).  
2.1.3.5 The IRP/IRE regulatory network in other pathways 
Apart from the IREs found in transferrin receptor 1, DMT1, H- and L-ferritins, ferroportin, 
Alas2, Aco2 and DSdhB already discussed, it seems that the IRP/IRE regulatory network is 
wider than previously thought and may regulate pathways not directly related to iron 
homeostasis (Sanchez et al., 2011). 
Several groups have reported new IRE-containing mRNAs using different approaches 
By computational searches, an IRE was described in the 3’ UTR of the human MRCKǂ, also 
known as CDC42 binding protein kinase alpha (CDC42BPA) (Cmejla et al., 2006) (see Figure 
5). This kinase is the effector of a small Rho GTPase Cdc42 and promotes cytoskeletal 
reorganization. The authors claim that the mRNA of MRCKǂ is regulated by iron in a 
similar but less intense way to TFR1 mRNA and they proposed a novel molecular link 
between iron metabolism and the cellular cytoskeleton. 
Members of our group have found a conserved and functional 3’ UTR IRE in a splicing 
mRNA isoform coding for CDC14A, a highly evolutionarily conserved cell-cycle 
phosphatase (Sanchez et al., 2006) (see Figure 5). The CDC14A mRNA and other mRNAs 
were bioinformatically predicted to bear a conserved IRE and subsequently spotted on a 
home-made iron-specific microarray. The CDC14A and HIF2ǂ mRNAs (see below) were 
isolated by IRP immunoprecipitation, using total RNA derived from human cell lines, and 
identified using this same iron-specific microarray. The mRNA levels of the human 
CDC14A IRE isoform were shown to be specifically increased upon iron deprivation and it 
is possible that the regulation of CDC14A by the IRPs participates in the cell-cycle arrest 
observed during iron scarcity in cells. This finding opens up new interesting links between 
iron metabolism and cell cycle regulation. 
The approach described above also revealed an atypical IRE in the 5’ UTR of HIF2ǂ mRNA, 
which encodes for a key transcription factor induced by lack of oxygen (hypoxia) or iron 
(Sanchez et al., 2007). The IREs of HIF2ǂ and DMT1 mRNAs have an additional bulge on the 
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3’ strand of the upper stem (see Figure 2). Under normoxic conditions, IRPs bind to the 5’ 
IRE of HIF2ǂ mRNA and repress its translation, whereas hypoxia de-represses HIF2ǂ 
mRNA translation by impairing IRP binding activity and prevents HIF2ǂ degradation by 
inhibiting prolyl hydroxylase activity. This mechanism was proposed to modulate the levels 
of erythropoietin, a major target of HIF2ǂ, adjusting the rate of red blood cell production to 
iron availability. Therefore, we discovered a negative feedback control of the HIF-mediated 
response under conditions of limited iron availability. HIF2ǂ also regulates the expression 
of genes involved in angiogenesis and vascularisation (i.e. VEGF, PDGF), but the effect of 
the IRP/IRE system on these HIF2ǂ targets has yet to be studied. To investigate the 
physiological and pathophysiological role of HIF2ǂ IRE in vivo and the effect of its ablation 
on haematopoiesis and cancer development it would be necessary to generate a knock-in 
mouse model, in which the IRE-IRP interaction is selectively disrupted.  
 
Fig. 5. Other poorly conserved IREs and the role of their encoded proteins. Apical loops and 
C-bulges are circled in blue. 5’ or 3’ location of the IRE and the specie where it is found are 
shown. The function of the encoded protein is shown in red. MRCKǂ: CDC42-binding 
protein kinase alpha, CDC14A: Cell division cycle 14A, Gox: Glycolate oxidase, AHSP: 
Erythroid-associated factor, NDUFS1: NADH-ubiquinone oxidoreductase Fe-S protein, ǃ-
APP: Amyloid beta A4 precursor protein. 
Additional non-canonical and poorly conserved IREs have been described in different 
mRNAs.  
An IRE-like structure is present in the 3’UTR of mouse glycolate oxidase (Gox), a liver-
specific mRNA (Kohler et al., 1999) (see Figure 5). This novel IRE-containing mRNA was 
detected by enrichment of mRNAs using an affinity IRP1 matrix; positive mRNAs were then 
cloned in a cDNA library and screened by RNA-protein band shift assays. The main 
difference from a canonical IRE was the presence of a mismatched (A:A) nucleotide pair in 
the middle of the upper stem. This IRE-like sequence exhibited strong binding to IRPs at 
room temperature but not at 37 degrees and translational regulation in response to iron 




construct. These observations brought the authors to claim that such an IRE is not functional 
in cells. 
In primate sequences of the mRNA encoding for the alpha-haemoglobin-stabilizing protein 
(AHSP), a molecular chaperone that binds and stabilizes free alpha-globin during 
haemoglobin synthesis, a 3’ UTR IRE-like sequence was detected using an RNA folding 
program (Meehan & Connell, 2001) (see Figure 5). The main difference between this and a 
canonical IRE is the presence of an A8 bulge nucleotide instead of a C8 and in 2 additional 
unpaired nucleotides (UG) at the 3’ end of a typical CAGUGH apical loop. Although this 
IRE-like structure binds IRPs poorly in electrophoretic mobility shift assays, in cytoplasmic 
extracts the AHSP mRNA co-immunoprecipitates with IRPs via this element and this 
interaction is inhibited by iron. The IRP- AHSP interaction enhances AHSP mRNA stability 
in erythroid and heterologous cells.  
The human 75-KDa subunit of mitochondrial complex I (NDUFS1) is regulated by iron at 
the protein but not at the mRNA level (Lin et al., 2001). In the 5’ UTR of this mRNA a motif 
element that resembles an IRE was identified; however this element does not contain a C8 
bulged nucleotide and in it the apical loop (CAGAG) is formed by only five nucleotides 
instead of six (see Figure 5). Interestingly, this element is bound by a specific cytoplasmic 
protein, which is neither IRP1 nor IRP2 and the binding interaction can be competed with 
ferritin IRE and was affected by iron status. It has been suggested that NDUFS1 may be 
regulated by a novel IRP/IRE system.  
A type II IRE motif was found in the 5’ UTR of the human mRNA encoding the Alzheimer’s 
beta amyloid precursor protein (ǃ-APP), which functions as a translational control element 
via interaction with IRP1 (Rogers et al., 2002) (see Figure 5). This IRE is structurally different 
from the one presented earlier. Also, a very atypical IRE motif was predicted in the 5’UTR of 
the human ǂ-synuclein mRNA involved in Parkinson’s disease (see Figure 5); however, no 
functional characterization was reported (Friedlich et al., 2007). As brain iron homeostasis is 
disrupted in a number of neurodegenerative disorders, a deeper understanding of the 
functional IRP regulation of mRNAs involved in these diseases is of great interest.  
IRE-like structures were reported in the Bacillus subtilis genome and the aconitase of this 
gram-positive bacterium was described as an RNA-binding protein (Alen & Sonenshein, 
1999). B. subtilis aconitase mutants demonstrate that its non-enzymatic activity is important 
for sporulation, an iron-dependent process. The authors suggest that bacterial aconitases, 
like their eukaryotic homologues, are bi-functional proteins, showing aconitase activity in 
the presence of iron and RNA binding activity in iron-deprived conditions.  
A recent genome-wide study was carried out by our group to identify the whole repertoire 
of mRNAs that can interact with the IRPs (Sanchez et al., 2011). IRP1/IRE and IRP2/IRE 
mRNP complexes were immunoselected and the mRNA composition of the IRP-binding 
transcripts was determined using whole-genome microarrays. In this strategy we used total 
mRNA from five different mouse tissues relevant for iron metabolism (liver, duodenum, 
spleen, bone marrow and brain). Using this approach novel mRNAs that can bind to both 
IRPs (n=35), as well as specific-IRP1 mRNAs (n=101) and specific-IRP2 mRNAs (n=113) 
were detected for the first time. Bioinformatic analysis to predict IRE motifs in the novel IRP 
target mRNAs was carried out using the newly developed software called SIREs (Searching 
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for IREs, (Campillos et al., 2010), see section 2.1.1.1) also designed by our group. Some of the 
novel IRP target mRNAs were tested in vitro in IRP1 competitive binding assays. We also 
undertook a proteomic approach to identify iron and/or IRP-modulated proteins in an iron-
regulated mouse hepatic cell line and in bone marrow derived macrophages from IRP1- and 
IRP2-deficient mice. We are currently proceeding with the functional characterization (iron 
and IRP regulation) of these novel mRNAs to discover and connect known and new cellular 
functions that need to respond to changes in iron metabolism.  
3. Diseases affecting the IRP/IRE regulatory network 
In humans, several diseases are caused by the disturbance of systemic or cellular iron 
homeostasis. In particular for cellular iron misregulation involving the IRP/IRE regulatory 
system several diseases have been reported and are described in the sections below.  
3.1 Hyperferritinemia-cataract syndrome (OMIM #600886) 
“Hereditary Hyperferritinemia-Cataract Syndrome” (HHCS) was first described in 1995 
(Bonneau et al., 1995; Girelli et al., 1995) as an autosomal dominant inherited disorder 
characterised by markedly elevated serum ferritin levels (≥1000 ng/ml) without iron 
overload and congenital early onset bilateral cataract.  
The absence of iron overload in HHCS patients suggested that the elevated serum ferritin 
resulted from misregulation of L-ferritin expression. Analysis of the L-ferritin genetic locus 
in HHCS patients led to the identification of heterozygous mutations occurring within the 
IRE of the L-ferritin gene. An inability to block ferritin translation in this disorder has been 
demonstrated by experiments using cultured lymphoblastoid cells from affected patients: 
the mutation abolishes the binding of IRPs and leads to constitutively high levels of L-
ferritin synthesis (Cazzola et al., 1997). The clinical phenotype of these mutations is only the 
presence of bilateral congenital cataracts. Although the mechanism of cataract formation is 
not clear, the deposit of excess L-ferritin in the lens seems to be responsible. A 
comprehensive study of cataract features in several families affected by HHCS has been 
performed by Craig and colleagues (Craig et al., 2003). 
Since 1995, numerous mutations affecting the 5’ IRE of L-ferritin have been described, 
including deletions and point mutations (Millonig et al., 2010). A comprehensive revision of 
the described mutations in HHCS is shown in Figure 6. Most of the mutations discovered so 
far are located in the upper stem and the conserved hexa-nucleotide apical loop of the IRE. 
Historically, the L-ferritin IRE mutations have been described with the name of the city in 
which mutations were identified followed by the nucleotide position and change (i.e. 
Verona 1 (+41) C). Up to now, less than 90 families have been diagnosed with the disease 
around the world, so it appears to be uniformly widespread. Prevalence of this disease still 
needs to be precisely determined but it is estimated to be at least 1 in 200,000 according to 
the Orphanet database.  
Our group have recently diagnosed four Spanish families (ten individuals) affected by 
HHCS that present four previously described single point mutations in the IRE of the L-
ferritin (unpublished data, Figure 7). All our cases present high levels of serum ferritin and 





Fig. 6. Predicted secondary structure of the IRE motif in the 5’ UTR of the L-ferritin mRNA 
and reported mutations causing HHCS (name and position in blue and nucleotide change in 
red). The apical loop and the C8-bulge are circled in blue. The transcriptional start site is 
shown as (+1), and the first 77 nucleotides are shown in an extended stem-loop structure. 
Single nucleotide changes are depicted by arrows and nucleotide deletions are represented 
by brackets. 
In HHCS patients there is a marked phenotypic variability with regard to ocular 
involvement, serum ferritin levels and age of cataract onset, even between subjects sharing 
the same mutation in the same family. This suggests that other environmental factors could 
be involved in the development of clinical symptoms in each person (Girelli et al., 2001). 
Although HHCS is an autosomal dominant disorder, a patient without family history has 
recently been reported (Cao et al., 2010). 
Because of the high levels of serum ferritin, some HHCS patients have been misdiagnosed 
with the iron-overload genetic disease Hereditary Hemochromatosis. These HHCS patients 
have been studied by liver biopsy and have developed iron-deficiency anemia after repeated 
venesections. A correct genetic diagnosis in HHCS patients is very important, as it will 
prevent unnecessary clinical tests and the implementation of inadequate treatments. For this 
reason, it is important to increase awareness of this rare pathology among pediatricians, 
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ophthalmologists, gastroenterologists, haematologists and general practitioners. Patients 
diagnosed with HHCS should be counselled regarding the relative harmlessness of this 
genetic disease, with early cataract surgery as the only clinical consequence. 
 
Fig. 7. Four Spanish families affected by hyperferritinemia-cataract syndrome reported in 
our laboratory. Family pedigrees are shown together with histograms reporting the 
nucleotide change and the mutation name and position. In the pedigrees, squares and circles 
symbolize males and females, respectively, and black symbols denote affected patients with 
hyperferritinemia and cataracts. Serum ferritin (ng/ml) values are indicated in affected 
individuals. Dashed symbols represent deceased individuals. Roman numerals indicate 
generations. Point mutations are located in the IRE structure of L-ferritin. 
3.2 Autosomal dominant Iron overload syndrome (OMIM +134770) 
An autosomal dominant iron overload syndrome has been described in a unique Japanese 
family by Kato and colleagues (Kato et al., 2001). In this family a point mutation (A49U) in 
the IRE of the H-ferritin gene was found. However, no other mutations in the IRE of the H-
Ferritin that affects the IRP/IRE binding have been reported by any other researchers, 
including a large study with subjects presenting abnormal serum ferritin values and 
abnormal iron status (Cremonesi et al., 2003). 
The proband described by Kato and collaborators was a woman showing high serum 
ferritin levels, iron overload and increased transferrin saturation. Authors also studied 




defined by elevated serum iron values and excessive iron deposition in liver and bone 
marrow evidenced by magnetic resonance imaging. Two of these three relatives also had 
elevated serum ferritin levels, but the proband’s daughter did not (Figure 8A).  
After excluding other causes of iron overload, they sequenced H- and L-ferritin cDNAs in 
the proband. A heterozygous single A-to-U conversion at position 49 inside the IRE was 
found in the sequence of the H-ferritin gene (see Figure 8B and 8C).  
 
Fig. 8. A mutation in the IRE of H-ferritin mRNA causes autosomal dominant iron overload. 
A. Pedigree of a family with dominant primary iron overload. Black symbols denote 
individuals showing the A49T genotype. Serum ferritin (ng/ml) values are indicated. The 
arrow indicates the proband (II-4). B. Histograms for a normal relative and the proband 
showing the sequence of H-ferritin where the mutation (+49A>T) was found in 
heterozygous state. C. Predicted secondary structure of the 5’ IRE in H-ferritin subunit 
mRNA. The mutation position (+49) is based on the human H-ferritin chain mRNA 
sequence L20941. The A49U mutation affects the second nucleotide of the IRE loop. Adapted 
from Kato et. al. 2001. 
The A49U mutation affects the second base of the IRE apical loop (CAGUG), a nucleotide 
that was reported to have direct protein contact with IRP1 in the IRP1/IRE crystallography 
structure (Walden et al., 2006). This mutation was also detected in the genomic DNA of the 
four relatives who had iron overload, but not in the genomic DNA of 42 unrelated control 
subjects. The segregation of the mutation and iron overload in the family members was 
consistent with an autosomal dominant pattern of inheritance. The +49A>T mutation was 
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considered a novel cause of hereditary iron overload, most likely related to an impairment 
of the ferroxidase activity generated by H subunit (Kato et al., 2001).  
3.3 Mutations in the ferroportin 5’ IRE 
A radiation-induced mouse model with a 58 bp deletion in the 5’ UTR of ferroportin gene, 
including the IRE motif, has been described (Mok et al., 2004). These mice present 
erythropoietin-dependent polycythaemia when the mutation is in the heterozygous state 
and microcytic hypochromic anaemia in homozygosity. Both defects in erythropoiesis were 
transient and corrected in early adulthood by the action of hepcidin.  
A 5’ UTR mutation has been detected in a patient with iron overload due to Hereditary 
Hemochromatosis type 4, also known as ferroportin disease (Liu et al., 2005). The mutation 
is located seven nucleotides downstream of the ferroportin IRE and may alter the IRE-IRP 
recognition, although this has not been proven.  
3.4 IRPs in iron-sulphur cluster deficiency anaemias 
As mentioned in section 2.1.2.1, IRP1 has a dual function; firstly as a cytosolic aconitase 
when it incorporates an iron-sulphur cluster, and secondly as an RNA-binding protein 
when this cluster is removed in iron-deprived conditions. The formation and assembly of 
iron-sulphur clusters in the cell is therefore very important for the regulation of IRP1 
activity. 
A novel disorder affecting the iron/sulphur cluster biogenesis has been described in a 
patient with a recessive form of inherited sideroblastic anaemias and a zebrafish model with 
severe hypochromic anaemia, the shiraz mutant (Camaschella et al., 2007; Wingert et al., 
2005). Both phenotypes are due to a mutation in the GLRX5 gene, which encodes for a 
mitochondrial protein important for iron/sulphur cluster biogenesis. The observed anaemia 
is the result of GLRX5 deficiency that increases IRP1 activity in the absence of iron/sulfur 
clusters which hampers its conversion to an aconitase. Increased IRP1 IRE binding activity 
leads to Alas2 translational repression and cytosolic iron depletion that also activates IRP2, 
which further contributes to Alas2 blocking. The described patient bears a homozygous 
mutation that interferes with intron 1 splicing and drastically reduces GLRX5 mRNA levels. 
Clinically this patient presents with iron overload and mild sideroblastic anaemia 
(Camaschella et al., 2007). Surprisingly, the anaemia in the patient was worsened by blood 
transfusions but partially reversed by iron chelation, presumably because iron chelation will 
redistribute iron to the cytosol, which might decrease IRP2 excess, improving haem 
synthesis and anaemia. The discovery of this disease establishes a link between two 
pathways of mitochondria iron utilization: haem biosynthesis and iron/sulphur cluster 
biogenesis. 
X-linked sideroblastic anaemia with ataxia (XLSA/A) is another disease affecting the 
iron/sulphur cluster (ISC) pathway. XLSA/A is a rare inherited disorder characterized by 
mild anaemia and ataxia and is caused by mutations in the ABCB7 gene, which encodes a 
member of the ATP-binding cassette transporter family involved in the transport of ISC 
from the mitochondria to the cytoplasm. The liver-specific conditional knockout of Abcb7 




IRP1 RNA binding activity, with concomitant increase in TFR1 expression and hepatic iron 
overload (Pondarre et al., 2006). However, increased levels of TFR1 proteins were attributed 
to IRP2 stabilizing effects rather than IRP1, as surprisingly it was found that IRP1 protein 
levels were reduced in these mice due to an iron-dependent IRP1 protein degradation. RNA 
binding activity and protein levels of IRP2 were found to increase, despite the apparent 
cellular iron overload that does not seem to be appropriately sensed by IRP2.  
In conclusion, ISC deficiency leads to dysregulated activation of IRP1 and IRP2 and it seems 
that IRP RNA binding activity may respond more to the flux of iron through a specific 
metabolic pathway, such as the ISC assembly, than to the absolute levels of cellular iron. 
Therefore, major problems associated with these disorders seem to be a consequence of 
inappropriate regulation of downstream targets of cytosolic IRPs, rather than ISC deficiency 
per se. 
3.5 Other pathophysiological roles for IRPs 
Brain homeostasis of trace metals such as copper and iron is dysregulated in neurological 
disorders such as Alzheimer's disease, where increased iron and decreased copper levels are 
observed. Young mice with targeted deletion of IRP2 have significantly less brain copper 
and the expression of ǃ-APP is significantly up-regulated in the hippocampus (Mueller et 
al., 2009). In humans, polymorphisms in the promoter region of IRP2 gene are statistically 
associated with Alzheimer’s disease (Coon et al., 2006). This finding awaits further 
confirmation in independent and larger studies, and also the functional significance of these 
polymorphisms needs to be clarified. Mouse work on the role of IRP2 in neuropathology is 
somewhat controversial. One group have reported that aging IRP2 KO mice develop a 
progressive neurodegenerative disorder (LaVaute et al., 2001), while the IRP2 KO mice 
generated by an independent group using a different targeting strategy do not manifest 
severe neurodegeneration, despite performing poorly in neurobehavioural tests (Galy et al., 
2006). In spite of the observed iron accumulation in the neurons of the substantia nigra of 
Parkinson’s patients, ferritin levels are not up-regulated. This effect was attributed to high 
levels of IRP1-IRE binding activity, which is insensitive to iron concentration, probably 
because of a different compartmentalization of the iron (Faucheux et al., 2002). IRP-1 and -2 
activities were found to be increased in brain cells in a Transmissible Spongiform 
Encephalopathy mouse model (Kim et al., 2007). 
Genome-wide association studies in combination with expression profiling implicate IRP2 
as a susceptibility gene in chronic obstructive pulmonary disease (COPD) (DeMeo et al., 
2009). This study also found that IRP2 protein and mRNA were increased in lung-tissue 
samples from COPD subjects in comparison with controls. The association of IRP2 SNPs 
with COPD has been recently replicated by a second group (Chappell et al., 2011). 
IRPs have been involved in cancer biology. The over-expression of IRP1 suppresses growth 
of tumour xenografts in nude mice (Chen et al., 2007). In these experiments, stable 
transfected and tetracycline inducible (tet-off system) H1299 lung cancer cells with IRP1 
wild-type or a mutated IRP1 version that constitutively binds IRE were used; these cells and 
control cells were then transplanted into nude mice to study their tumourogenic effects. 
Interestingly, similar experiments with IRP2 showed the opposite behaviour, a pro-
oncogenic activity of the over-expression of IRP2 that was attributed to an IRP2-specific 
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domain of 73 amino acids (Maffettone et al., 2010). In both systems the expression of ferritin 
and TFR1 was similar; however, tumours over-expressing IRP1 and IRP2 exhibited distinct 
gene-expression profiles, suggesting that IRPs may differentially modulate cancer growth 
by regulating a different subset of genes, which could be related or not to iron homeostasis. 
Indeed, the IRP2 pro-oncogenic activity was associated with an increase in the 
phosphorylation of ERK ½, an extracellular signal-regulated kinase, and with high levels of 
the proto-oncogene c-myc that was previously implicated in the transcriptional activation of 
IRP2 (Wu et al., 1999). The understanding of the molecular pathways that involves IRPs in 
cancer biology is very incipient and further work is required. 
4. Small molecules and drugs affecting the IRP/IRE regulatory network 
Small-molecules that selectively bind to and modulate the IRP-IRE interaction, by inhibiting 
or enhancing it, have been described in two studies. 
By chemical footprinting assay the natural product yohimbine was found to selectively 
interfere with the ferritin IRE and inhibit IRP-ferritin IRE binding, increasing the rate of 
ferritin biosynthesis in cell-free extracts (Tibodeau et al., 2006). The selective effect of this 
compound proved that small-molecules can distinguish between different members of the 
IRE family. Further development of therapeutic approaches, with this or similar 
compounds, could be used to increase iron-storage capacity in pathological conditions that 
require it, such as iron-overload diseases.  
Using a cell-based screen method several small molecules that decrease HIF2ǂ translation 
by enhancing the binding of preferentially IRP1 to the 5’ IRE present in HIF2ǂ were 
described by Zimmer and collaborators (Zimmer et al., 2008). An enhancer effect of these 
compounds on the IRP-IRE binding was also observed for transferrin receptor 1 (TFR1), 
increasing its mRNA stability. As hypoxia inducible factors (HIFs) are linked to cancer 
progression, angiogenesis and inflammation, HIF inhibitors (like these compounds) could 
be used in antineoplastic and anti-inflammatory therapies. 
Other small molecules and drugs that interfere with iron uptake via DMT1 or transferrin 
receptor 1 have been reported but their mechanism of action does not seem to be related 
with the modulation of the IRP-IRE regulatory system (Brown et al., 2004; Horonchik & 
Wessling-Resnick, 2008; Wetli et al., 2006). 
5. Conclusions and future perspectives 
In recent years, impressive progress has been made in unraveling the control of iron 
homeostasis by the IRP/IRE regulatory system. However, many details remain unanswered 
and require further investigation. For instance, a recent high-throughput screening study 
has considerably enlarged the number of known IRP-binding mRNAs, extending the IRP 
functions to multiple pathways, including cancer biology (Sanchez et al., 2011). Now the 
challenge is to uncover the role and mechanisms of action of these new mRNAs regulated 
by IRPs with studies ranging from basic research to medical and applied physiology.  
Additional IRP mouse models with cell-specific ablation or over-expression in an inducible 
or non-inducible system will provide valuable information concerning the 




an IRE and the physiological role that IRPs exert on them in vivo, the generation of animal 
models with a particular disrupted IRE would be of great interest. A deeper study into 
several research fields affecting iron and IRP misregulation (such as iron brain homeostasis, 
iron in cancer biology and iron implication in immunity and infection) will have 
implications for the development of therapies for common and rare disorders related to the 
IRP/IRE regulatory system. 
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